|Bid||13.59 x 0|
|Ask||13.60 x 0|
|Day's Range||13.56 - 13.83|
|52 Week Range||12.51 - 16.57|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||43.60|
|Forward Dividend & Yield||0.18 (1.28%)|
|1y Target Est||12.43|
ResMed today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes.
Now offers “tube-up” design options for nasal and nasal pillows mask wearers, providing even more flexibility and choice to help users sleep better in any position
HMEs can now see workflow insights, KPI tracking, and peer benchmarking on one auto-produced dashboard to enhance business decision-making
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Brand-agnostic solution helps HMEs provide timely PAP replacement supplies to sleep apnea patients, increases long-term adherence and improves satisfaction
ResMed (RMD) (RMD.AX) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com.
ResMed Inc NYSE:RMDView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for RMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold RMD had net inflows of $5.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
ResMed (NYSE: RMD, ASX: RMD), a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, today announced that is has completed the acquisition of HB Healthcare (HBH) to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. HBH, a fast-growing privately owned South Korean home medical equipment provider, serves both reimbursed and cash-pay customers of sleep and respiratory care devices.
- Home infusion therapy providers and HME pharmacies benefit from feature-rich functionality within a single software solution for all clinical, billing and reporting needs
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BLOOMINGTON, Minn., Feb. 27, 2019 -- MatrixCare announced today that it has entered into a National Pharmacy Integration and Electronic Medication Administration Record (eMAR).
MADISON, Wis., Feb. 21, 2019 /PRNewswire/ -- The vast majority of people with asthma may be using their inhalers incorrectly, potentially making their medicine less effective and increasing their risk of asthma attacks, according to new research published in The Journal of Allergy and Clinical Immunology: In practice by digital therapeutics company Propeller Health, in partnership with the University of Colorado School of Medicine and Children's Hospital Colorado. Many asthma medicines require that patients take two "puffs" of their inhaler to receive the prescribed dose.
New Zealand medical device maker Fisher & Paykel Healthcare Corp Ltd and U.S. rival ResMed Inc have agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees. In a joint statement on Thursday, the companies agreed to end all ongoing infringement cases and said neither would admit liability or make any payment. Fisher & Paykel shares were 6.9 percent higher after the announcement, reaching a more than four-month peak, whereas ResMed's Australian depository receipts were 1.1 percent firmer.
Medical device maker Fisher & Paykel Healthcare and U.S.-based ResMed on Thursday agreed to settle disputes over patent infringement, bringing to an end a tussle spanning the globe. The two companies had ...
ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. The settlement involves no payment or admission of liability by either side. “I am pleased we were able to resolve these disputes,” said ResMed CEO Mick Farrell.
Investorideas.com, a leading investor news resource covering technology and healthcare stocks releases a snapshot looking at how healthcare is changing in the digital age. Investorideas recently reported on how Digital Health technologies enabling out-of-hospital care and monitoring are forecast to grow by 30 percent and cross the $25 billion mark. In the article, Kamaljit Behera, Industry Analyst, Transformational Health, said, "In this highly digitized environment, artificial intelligence (AI) will permeate the life sciences ecosystem, and its use in healthcare IT (HIT) is likely to cross $1.7 billion by the end of 2019.
The Dow Jones Industrial Average rose 0.8% to close at 24,737.20 on a report that the Fed might stop winding down its bond holdings earlier than expected.
Stocks that moved substantially or traded heavily Friday: Western Digital Corp., up $3.02 to $43.16 The hard-drive maker reported better-than-expected quarterly financial results and an upbeat forecast. ...
The San Diego company reported a 9% increase in adjusted revenue to $651.1 million but lagged Wall Street's expectations of $667 million. "We had a solid quarter with top-line growth and gross margin expansion, as well as continued fiscal discipline to drive leverage and improved operating profit," said Mick Farrell, ResMed's CEO. Through the first half of the company's fiscal year, ResMed has posted an increase of 11% on adjusted revenue while earnings have gained 9%.